Germany’s two leading specialist societies have published a revised S3 guideline that moves systematic early-pregnancy diabetes screening from expert consensus into formal, evidence-based recommendations, the German Society of Gynecology and Obstetrics (DGGG) and the German Diabetes Society (DDG) announced in November 2026, according to Dggg.
The guideline, coordinated under the AWMF registry, calls for risk-factor assessment at the first prenatal visit and targeted glucose testing in the first trimester to catch overt diabetes and “early GDM” before the standard 24-to-28-week oral glucose tolerance test (oGTT). Until now, early screening has not been part of the federal maternity-care directives (Mutterschaftsrichtlinien); an application to the Joint Federal Committee (G-BA) to embed it is in preparation, the societies said.
“We increasingly see pregnant women in whom the diagnosis is only made at the mandatory 24-to-28-week screening and the child already shows excessive, diabetes-typical growth,” said Prof. Dr. med. Ute Schäfer-Graf, DGGG guideline coordinator at St. Joseph Hospital Berlin.
The update also adds metformin as an approved alternative to insulin for women who need pharmacologic therapy, recommends induced delivery at 39+0 weeks when estimated fetal weight exceeds the 95th percentile, and mandates postpartum glucose testing at 6–12 weeks plus structured long-term follow-up for cardiovascular and renal risk.
Earlier detection to close a treatment gap
Rising prevalence of type 2 diabetes in younger women means overt hyperglycemia often exists weeks before the routine oGTT window, the guideline authors write. The new algorithm therefore requires clinicians to document risk factors — age, BMI, family history, high-risk ethnicity, previous GDM — at the booking visit. If any are present, a targeted glucose measurement should follow immediately.
When fasting glucose or HbA1c meets non-pregnant diabetes thresholds, treatment starts without delay, aligned with the companion S3 guideline “Diabetes and Pregnancy” (AWMF 057/023).
If values meet the lower “early GDM” cut-offs used later in pregnancy, the guideline recommends lifestyle intervention and monitoring but stops short of routine pharmacotherapy, citing insufficient evidence for benefit.
Women who test negative in the first trimester still receive the universal 75 g oGTT at 24–28 weeks; those already treated do not repeat it.
Metformin enters the formulary
For the first time, the guideline explicitly permits metformin as an alternative to insulin when medical nutrition therapy and glucose monitoring fail to achieve targets. The option applies to women with GDM and overweight or obesity who are motivated to limit gestational weight gain.
“Women with GDM and overweight or obesity should be motivated to aim for minimal weight gain, and those requiring medication can also be offered metformin as an alternative to insulin,” said PD Dr. med. Katharina Laubner, DDG guideline coordinator at University Hospital Freiburg.
Self-monitoring frequency should be limited to the “decision-relevant minimum” to reduce burden, the authors add.
Induction recommended for large-for-gestational-age fetuses
Fetal macrosomia — large-for-gestational-age newborns — drives shoulder-dystocia and cesarean risk. The guideline now recommends offering induction at 39+0 weeks when ultrasound estimates exceed the 95th percentile. At an estimated weight above 4,250 g, clinicians must counsel on shoulder-dystocia risk, especially with a pronounced head-to-abdomen discrepancy.
Because even well-controlled GDM carries a relevant risk of neonatal hypoglycemia, delivery should occur in a unit with continuous pediatric presence and no spatial separation of labor ward and nursery, avoiding mother–infant transfer.
Postpartum roadmap
Before discharge, women treated with medication during pregnancy must have persistent hyperglycemia excluded. All women with GDM should receive a postpartum oGTT at 6–12 weeks, screening for peripartum depression, and counseling on exclusive breastfeeding for six months with continued breastfeeding after complementary feeding.
Long-term, the guideline stresses structured recall for diabetes, metabolic syndrome, cardiovascular and chronic kidney disease surveillance, noting that offspring risk for obesity and metabolic syndrome is strongly mediated by maternal adiposity and shared genetics and lifestyle.
S3 guideline lacks binding force pending G-BA decision
The document carries AWMF S3 status — the highest methodological level in Germany — but remains a clinical recommendation without binding legal force or liability protection. The pending G-BA application will determine whether early screening becomes a reimbursed standard in statutory maternity care.
FAQ
When does the new early screening happen?
Universal oGTT at 24–28 weeks remains standard for all others.
Is metformin now first-line for GDM?
No. Lifestyle modification remains first-line; metformin is an alternative to insulin when pharmacotherapy is needed, not a replacement for diet and exercise.
Does the guideline change the legal maternity-care directives immediately?
No. An application to the G-BA is in preparation; until it is adopted, early screening is a guideline recommendation, not a mandated benefit.
Related reading